Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07098247

Exploring Photon-Counting CT for Enhanced Target Delineation and Dose Accuracy in Personalized Radiotherapy - ANTHEM

Status
Recruiting
Phase
Study type
Observational
Enrollment
500 (estimated)
Sponsor
Istituto Clinico Humanitas · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Radiotherapy remains a cornerstone of oncology care, particularly for rare or orphan cancers and chronic oncologic and rare non oncologic conditions, where precision and individualized treatment planning are necessary. Advances in imaging technologies are crucial to overcome the challenges posed by these cases, especially in achieving accurate tumor delineation and dose delivery. Photon-counting CT (PCCT) represents a transformative step forward in imaging technology. Unlike conventional energy-integrating CT, PCCT offers a) superior spatial resolution, enabling clearer visualization of tumor margins and fine anatomical structures, b) enhanced tissue characterization, allowing better differentiation between tumor tissues and normal tissue; c) spectral imaging capabilities, facilitating improved dose calculations. These attributes are particularly advantageous in high-precision radiotherapy techniques, such as stereotactic body radiotherapy (SBRT) or proton therapy, where small errors in target delineation or dose delivery can significantly impact treatment outcomes. However, very limited data reporting the clinical use of PCCT for RT planning are available.

Conditions

Timeline

Start date
2025-04-04
Primary completion
2027-05-01
Completion
2027-05-01
First posted
2025-08-01
Last updated
2025-08-01

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT07098247. Inclusion in this directory is not an endorsement.